Фармацевтичний журнал (Aug 2018)
The development of technology of Fludeoxyglucose (18F) for injection, laboratory analysis methods
Abstract
18F-Fluorodeoxyglucose has optimal characteristics for use in nuclear medicine and is a priority among radiopharmaceuticals for the diagnosis of cancer by positron emission tomography (PET). 18F-Fluorodeoxyglucose has the longest half-life with the lowest energy of radiation, it allows to obtain PET images of high contrast at low dose loading on the patient. Low energy positron radiation provides high spatial resolution of PET images. However, the half-life of 18F-Fluorodeoxyglucose is large enough to allow the transportation of radiopharmaceuticals from the centralized production site to diagnostic centers with PET scanners (the so-called PET satellite concept), and to extend the time limits of PET research and synthesis of radiopharmaceuticals [1]. The study is the development of technology and quality control methods to ensure quality at all stages of the production of radiopharmaceuticals 18F-Fluorodeoxyglucose, injection. There was justified 18F-Fluorodeoxyglucose production technology and quality control at all stages of production, based on complex research in the department producing radiopharmaceuticals Ukrainian Center of radiosurgery consisting Clinical Hospital «Feofaniya». Object of study – 18F-Fluorodeoxyglucose, injection, injection is used in nuclear medicine for PET diagnosis of cancer. We used the biopharmaceutical and pharmaceutical methods. For the first time based pharmaceutical research was the rational technology of diagnostic radiopharmaceuticals 18F-Fluorodeoxyglucose, injection for use in PET diagnosis of cancer patients. Methods of controlling drug 18F-Fluorodeoxyglucose, injection according monographs of the State Pharmacopoeia of Ukraine. On the basis of the analysis developed by established methods of control performance specifications and shelf life of radiopharmaceuticals 18F-Fluorodeoxyglucose, injection.
Keywords
